JNJ wants to move higher but it may be better to remain cautious.
Word is out that a Moderna experimental melanoma vaccine combined with Merck's Keytruda reduced the risk of relapse in people with skin cancer in a trail.
The charts of the biopharmaceutical company that focuses on neurodegenerative diseases indicate short-term caution but long-term promise.
Let's check the charts but be prepared for volatility.
Let's review the charts and indicators.
Let's check the charts after a fundamental buy call.
Shares of SUPN finally break out on the upside.
We have two price targets.
Let's see how traders could react to the latest news.
These kind of names are in short supply in the current market.